CN1220491C - 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物 - Google Patents

非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物 Download PDF

Info

Publication number
CN1220491C
CN1220491C CNB008111642A CN00811164A CN1220491C CN 1220491 C CN1220491 C CN 1220491C CN B008111642 A CNB008111642 A CN B008111642A CN 00811164 A CN00811164 A CN 00811164A CN 1220491 C CN1220491 C CN 1220491C
Authority
CN
China
Prior art keywords
testosterone
use according
therapeutic effect
estrogen
women
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008111642A
Other languages
English (en)
Chinese (zh)
Other versions
CN1367698A (zh
Inventor
T·罗萨里奥－简森
N·A·梅泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Finance LLC
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of CN1367698A publication Critical patent/CN1367698A/zh
Application granted granted Critical
Publication of CN1220491C publication Critical patent/CN1220491C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB008111642A 1999-06-11 2000-06-09 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物 Expired - Fee Related CN1220491C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13932399P 1999-06-11 1999-06-11
US13885199P 1999-06-11 1999-06-11
US13885499P 1999-06-11 1999-06-11
US60/138,851 1999-06-11
US60/138,854 1999-06-11
US60/139,323 1999-06-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510092033 Division CN1739527A (zh) 1999-06-11 2000-06-09 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物

Publications (2)

Publication Number Publication Date
CN1367698A CN1367698A (zh) 2002-09-04
CN1220491C true CN1220491C (zh) 2005-09-28

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008111642A Expired - Fee Related CN1220491C (zh) 1999-06-11 2000-06-09 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物

Country Status (25)

Country Link
US (3) US6583129B1 (https=)
EP (1) EP1189619A4 (https=)
JP (2) JP5184727B2 (https=)
KR (2) KR20070063609A (https=)
CN (1) CN1220491C (https=)
AR (1) AR024566A1 (https=)
AU (1) AU775145B2 (https=)
BR (1) BR0011740A (https=)
CA (1) CA2376797C (https=)
CO (1) CO5180583A1 (https=)
CZ (1) CZ299198B6 (https=)
HK (1) HK1048269B (https=)
HU (1) HUP0301813A2 (https=)
IL (1) IL147010A0 (https=)
MX (1) MXPA01012769A (https=)
MY (1) MY126960A (https=)
NO (1) NO20016046L (https=)
NZ (1) NZ516502A (https=)
PE (1) PE20010404A1 (https=)
PL (1) PL352250A1 (https=)
SA (1) SA00210404B1 (https=)
SK (1) SK18212001A3 (https=)
TR (1) TR200200406T2 (https=)
TW (1) TWI281398B (https=)
WO (1) WO2000076522A1 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
IL159415A0 (en) * 2001-06-18 2004-06-01 Noven Pharma Enhanced drug delivery in transdermal systems
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
PL211339B1 (pl) * 2001-07-09 2012-05-31 Zonagen Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
JP2005512995A (ja) * 2001-11-09 2005-05-12 ファイザー ヘルス アーベー 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
CA2481310A1 (en) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Step-down estrogen therapy
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
AU2003221715A1 (en) * 2002-06-14 2003-12-31 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
EP2301549A1 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
CA2595363C (en) * 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
US20060210645A1 (en) * 2005-03-02 2006-09-21 Du Mee Charles P Pharmaceutically acceptable carrier for ophthalmic compositions
EP1865938A4 (en) * 2005-03-22 2008-09-24 Repros Therapeutics Inc DOSAGE SCHEMES FOR TRANS-CLOMIPHENE
JP2009503670A (ja) * 2005-07-27 2009-01-29 インゲニア・テクノロジー・リミテッド 真正性検証
GB0523550D0 (en) * 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
WO2008040488A1 (en) 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
SG185311A1 (en) 2007-10-16 2012-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
WO2010000011A1 (en) * 2008-07-04 2010-01-07 The Heart Research Institute Ltd The use of androgens for vascular regeneration and endothelial repair
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
RU2695351C2 (ru) 2012-12-05 2019-07-23 Дже Нютриентс, Инк. Применение экстракта пажитника для усиления женского либидо
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP2968365A1 (en) * 2013-03-15 2016-01-20 Malhotra, Raman Systemic administration of androgen in treating dry eye syndrome
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
AU2019299538B2 (en) 2018-07-05 2025-05-08 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US4210664A (en) 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1731157A3 (en) 1998-06-11 2009-07-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması

Also Published As

Publication number Publication date
KR20020011437A (ko) 2002-02-08
EP1189619A1 (en) 2002-03-27
US7186706B2 (en) 2007-03-06
JP2013049682A (ja) 2013-03-14
JP5184727B2 (ja) 2013-04-17
KR20070063609A (ko) 2007-06-19
NO20016046L (no) 2002-02-06
HK1048269A1 (en) 2003-03-28
US6583129B1 (en) 2003-06-24
NZ516502A (en) 2004-03-26
US8551516B2 (en) 2013-10-08
PL352250A1 (en) 2003-08-11
CN1367698A (zh) 2002-09-04
AU5475800A (en) 2001-01-02
CA2376797C (en) 2011-03-22
AU775145B2 (en) 2004-07-22
US20030153540A1 (en) 2003-08-14
CZ299198B6 (cs) 2008-05-14
BR0011740A (pt) 2002-05-14
HUP0301813A2 (hu) 2003-09-29
TR200200406T2 (tr) 2002-06-21
WO2000076522A1 (en) 2000-12-21
US20070190120A1 (en) 2007-08-16
MXPA01012769A (es) 2003-06-24
JP2003505345A (ja) 2003-02-12
SK18212001A3 (sk) 2002-04-04
CO5180583A1 (es) 2002-07-30
CZ20014499A3 (cs) 2002-05-15
CA2376797A1 (en) 2000-12-21
SA00210404B1 (ar) 2006-08-21
AR024566A1 (es) 2002-10-16
IL147010A0 (en) 2002-08-14
PE20010404A1 (es) 2001-04-09
MY126960A (en) 2006-11-30
NO20016046D0 (no) 2001-12-11
EP1189619A4 (en) 2004-06-09
TWI281398B (en) 2007-05-21
HK1048269B (zh) 2006-01-13

Similar Documents

Publication Publication Date Title
CN1220491C (zh) 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物
CN1243550C (zh) 雄－5－烯－3β,17β－二醇的药物组合物及其用途
CN1042296C (zh) 避孕用途的药物制剂的制备方法
US20030022877A1 (en) Method of increasing testosterone and related steroid concentrations in women
JPH02502724A (ja) 避妊を達成する組成物および方法
CN1334734A (zh) 三阶段口服避孕药
AU6265998A (en) Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
RU2234920C2 (ru) Введение непероральным путем андрогенных стероидов женщинам
CN1739527A (zh) 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物
HK1088240A (en) The use of non-oral androgenic steroids in the manufacture of medicine for improving elevated sex hormone binding globulin levels
AU2004222794B2 (en) Non-oral androgenic steroids for women
HK1098053A (en) PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
HK1037329B (en) PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
HK1061804B (en) Method of increasing testosterone and related steroid concentrations in women
HK1061804A1 (zh) 提高婦女睪酮和相關類固醇濃度的方法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050928

Termination date: 20130609